Celldex Therapeutics Inc's Customers Performance

Name: Celldex Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CLDX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CLDX's Source of Revenues		During the corresponding time, Celldex Therapeutics Inc saw a revenue deteriorated by -97.84 % year on year, sequentially revenue fell by -87.5 %. While revenue at the Celldex Therapeutics Inc 's corporate clients • List of CLDX Customers

for the same period Celldex Therapeutics Inc revnue deteriorated by -97.84 % year on year, sequentially revenue fell by -87.5 %.

• List of CLDX Customers

Celldex Therapeutics Inc's Business Units


Contracts and grants		100 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Celldex Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Celldex Therapeutics inc Contracts

Celldex Therapeutics Unveils Promising Preclinical Findings for CDX-622, Paving the Way for Breakthrough Treatments i...

In a groundbreaking presentation at the AAAAI 2025 conference, Celldex Therapeutics showcased compelling preclinical data for its bispecific antibody program, CDX-622. This innovative therapeutic candidate targets critical pathways involved in inflammatory skin diseases, demonstrating significant potential for future clinical applications.CDX-622 is engineered to inhibit the signaling of Stem Cell Factor (SCF) and Thymic Stromal Lymphopoietin (TSLP) two key mediators in the inflammatory cascade associated with various dermatological conditions. The preclinical results indicated that CDX-622 effectively suppresses SCF and TSLP-dependent inflammatory signatures in human skin models, marking a significant step ...

Celldex Therapeutics Initiates Phase 1 Healthy Volunteer Study of Bispecific Antibody CDX-622 for Inflammatory Diseases

: Celldex Therapeutics, Inc. has announced the commencement of a Phase 1a clinical trial for CDX-622, a bispecific antib...

Celldex Therapeutics Announces Breakthrough 52-Week Results for Barzolvolimab in Chronic Spontaneous Urticaria ...

In a landmark presentation at the European Academy of Dermatology and Venereology (EADV) 2024 Congress, Celldex Therapeutics announced compelling results from its Phase 2 study of Barzolvolimab in patients suffering from Chronic Spontaneous Urticaria (CSU). The study results demonstrated significant therapeutic benefits, with 71% of patients receiving the 150 mg dosage every four weeks achieving a complete response at the 52-week mark.Chronic Spontaneous Urticaria is an inflammatory skin condition characterized by the presence of hives or welts without an identifiable trigger, significantly impacting patients quality of life. The efficacy results obtained in this study are particularly promising, considerin...

This Celldex Therapeutics Barzolvolimab Demonstrates Remarkable Phase 2 Success in Chronic Sp...

Celldex Therapeutics Reports Impressive Phase 2 Study Results for Barzolvolimab in Chronic Urticaria at EAACI 2024 Celldex Therapeutics, Inc. (NASDAQ: CLDX), a leading biopharmaceutical company dedicated to developing disruptive therapies for complex conditions, recently unveiled compelling data from its Phase 2 study of barzolvolimab in treating chronic spontaneous urticaria (CSU). Presented at the European Academy of Allergy and Clinical Immunology (EAACI) 2024 conference, the results exhibited profound and statistically significant improvements in angioedema measurements across multiple barzolvolimab dose groups. This development highlights sustained activity with a rapid onset within just two weeks of t...

Promising Developments in Chronic Inducible Urticaria Treatment: Celldex Completes Patient Enrollment in Phase 2 Barzolvolimab Study

(NEJM) reports on an important development a...

CLDX's Stock Performance relative to it's Customers

CLDX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Celldex Therapeutics inc	2,641.34	5.79	-283.65	198
SUBTOTAL	0.00	0.00	0.00	-

Sources: Celldex Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Celldex Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Celldex Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.